ArticleAnnals of surgical oncology2025
The Metaplastic Conundrum: A National Cancer Database Analysis of Metaplastic versus Triple-Negative Ductal Breast Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subtype-specific sonographic signatures and clinicopathological features of metaplastic breast cancer: a 50-case cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistorically, treatment approaches for metaplastic breast cancer (MpBC) have mirrored that of triple-negative ductal breast cancer (TN-IDC), yet MpBC has persistently worse survival. This study describes rates and response to neoadjuvant systemic therapy (NAC) for MpBC and evaluates survival between triple-negative MpBC (TN-MpBC), biomarker-positive MpBC (nTN-MpBC), and TN-IDC by treatment approach.
methodsThe National Cancer Database was queried for females diagnosed with clinically non-metastatic MpBC or TN-IDC from 2011 to 2021. One-to-one propensity score matching between TN-MpBC and TN-IDC patients was performed.
resultsOf 5575 MpBC patients, surgery and chemotherapy rates were high. For patients who received systemic therapy and surgery, an adjuvant approach was favored; however, NAC for TN-MpBC increased from 18.3 to 31.5% by 2021. Higher rates of NAC non-response and lower overall survival were found among MpBC cohorts compared with TN-IDC. For MpBC, an adjuvant approach had significantly better survival than other systemic therapy sequences. When evaluated by pathologic response to NAC, a partial or non-response had worse survival compared with complete response or not undergoing NAC. On Cox proportional hazard regression of matched patients, NAC had an adjusted hazard ratio of 2.56 (1.36-4.79) compared with not undergoing NAC.
conclusionMpBC is predominantly treated with surgery and systemic therapy, with increasing rates of NAC for TN-MpBC. However, patients with MpBC have inferior survival to TN-IDC, and NAC for MpBC is associated with worse survival compared with other systemic therapy sequences, unless a complete pathologic response is achieved. These findings reinforce the need for systemic treatment sequence optimization for MpBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.